Animal studies fortify these findings with the observed reductions in hepatic steatosis, NAFLD score, liver fibrosis, ALT, SBP, DBP, MAP, renin, and infarct size. This evidence concerns the gene REN and metabolic dysfunction-associated steatotic liver disease.